 Dear Reader, A few weeks ago, my name appeared in the Epstein files. I won't dramatize it. I wasn't accused of anything. I wasn't involved. But I did something most people don't do when they see something that doesn't add up. I spoke up. Years ago, when I thought a financial tip might help law enforcement understand how Epstein operated, I shared it. Discreetly. Without expecting anything in return. That instinct... to step forward when something feels wrong... is the same one that led me to warn about the dot‑com bubble... the housing collapse... and several major market dislocations before they became obvious. And it's why I'm speaking up again now. Because something fundamental is shifting in America. The cost of living no longer matches how much money we make... We can't keep our promises to younger generations. And artificial intelligence is accelerating changes most people are not prepared for. One Wall Street strategist recently called what's coming a "violent reset." I agree with the direction, if not the language. There is a line forming between those who understand what's happening... and those who don't. I've laid out what I'm seeing and, more important, what you can do about it, in detail. Click here to read it while you still can. Regards, Whitney Tilson
Editor, Stansberry's Investment Advisory
Exclusive Article Core Scientific's $10 Billion AI Shift Unlocks Triple-Digit UpsideReported by Thomas Hughes. First Published: 3/4/2026. 
Key Points- Core Scientific is well-positioned to execute its strategy and realize its growing, greater-than-$10 billion revenue backlog.
- Analysts and institutional data reveal strong support and potential for robust upside.
- Short sellers pose a threat, along with the potential short-covering rally or squeeze.
- Special Report: Every morning, an AI ranks 357 stocks for you (From TradingTips)
Core Scientific's (NASDAQ: CORZ) stock has struggled for traction in early 2026, but don't be fooled. The company's strategic shift from Bitcoin mining to AI mining is gaining momentum and accelerating, and the company appears on track for robust, profitable growth in the coming years. Profitability is the key: revenue is forecast to exceed a 30% compound annual growth rate (CAGR) over the next five years, and the market seems to be undervaluing that outlook. Trading at roughly 35x earnings in early March, a sustained 30%+ CAGR would make the stock trade at under 10x earnings relative to the 2030 forecast. That valuation implies a potential 100% to more than 200% increase in the stock price by then. A 100% increase would simply bring this stock in line with broad-market averages for current-year earnings, assigning no premium for its growth or earnings quality. Core Scientific Reveals Traction With Business ShiftChina just banned critical mineral exports to U.S. defense contractors, cutting off the materials inside every F-35, nuclear submarine, and hypersonic missile at the source—China controls 80-90% of processing and just weaponized it. The Trump administration escalated immediately with Executive Order 14285 declaring seabed minerals a national security priority, and now $20 trillion worth of nickel, cobalt, copper, and manganese sits in potato-sized rocks on the Pacific Ocean floor with one micro-cap company launching its strategy within five days of the rule change, led by a 25-year deepwater veteran and trading at ~C$26 million while the sector leader sits at ~$2.74 billion. Read the full intelligence briefing now Core Scientific's fiscal Q4 2025 results were a mixed bag: revenue contracted and missed consensus, but several details offset that weakness. A central theme was the decline in Bitcoin and related revenue as operations pivot toward AI infrastructure services. While Bitcoin revenue fell, colocation services—backed by contracts with CoreWeave (NASDAQ: CRWV)—grew more than 250% year-over-year (YOY) and are expected to continue expanding rapidly over the next two to three years. Management plans to nearly double capacity by early next year and continue scaling to meet demand. Margin developments were mixed, but the net effect was ultimately favorable for investors. Key positives included a 330% increase in gross profit and a swing to net income from a loss. The negatives included negative adjusted EBITDA, driven by rapid expansion and reduced BTC operations; management expects this to be temporary. The company provided no specific guidance but said it will continue ramping revenue and capacity while monetizing its Bitcoin operations and related assets. The balance sheet presents a risk: the shareholder deficit widened in 2025. However, the risk appears manageable. Increased spending and cash burn are tied to rapid expansion intended to meet growing demand. The company also has over $10 billion in contracted revenue—equivalent to several decades of operation at the Q4 2025 income level. If Core Scientific continues executing its strategy, it should drive cash flow and profits as the investment cycle slows, and operational quality should improve materially. 
Analysts Affirm Core Scientific's Double-Digit Upside PotentialAnalysts reacted to the report with mixed sentiment but no dramatic changes. The first three revisions MarketBeat tracked included an upgrade to Buy, a reaffirmed Buy, and a reduced price target attached to an Overweight (Buy-equivalent) rating. Together, those moves reinforce the Moderate Buy consensus and align with the consensus price target of $25, which implies about 55% upside from early-2026 support levels. Institutional trends suggest these investors will buy the post-release dip and continue to support the stock. MarketBeat data show institutions—including public and private funds, hedge funds, and corporations—own roughly 99% of the shares, and they have been accumulating for six consecutive quarters. Trading activity has run at a balance of approximately $2.50 bought for every $1 sold on a trailing-twelve-month (TTM) basis, with buying accelerating sequentially in the back half of 2025 and into early 2026. That pattern suggests a meaningful tailwind, with a market floor forming and a rebound in price potentially a matter of timing. Price action isn't strong yet, but it indicates a market building a support base. The stock is compressing into a narrowing near-term range, sitting near the midpoint of its historical range, with stochastic indicators showing support. That setup makes a move toward the top of the historical range possible, though a stronger catalyst may be required for new highs. Despite the constructive outlook, short-sellers remain a risk and could cap gains in the $20–$22 area.
This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here. | 
No comments:
Post a Comment